ICER issues final report on VMAT2 inhibitors for tardive dyskinesia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2018 Category: Drugs & Pharmacology Source Type: news
All you need to know about akinesia
A look at akinesia, a condition where a person cannot move their muscles as they wish. Included is detail on the difference between akinesia and dyskinesia (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - December 10, 2017 Category: Neurology Tags: Parkinson's Disease Source Type: news
Medical News Today: All you need to know about akinesia
A look at akinesia, a condition where a person cannot move their muscles as they wish. Included is detail on the difference between akinesia and dyskinesia (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 10, 2017 Category: Consumer Health News Tags: Parkinson's Disease Source Type: news
What is the definition of akinesia?
A look at akinesia, a condition where a person cannot move their muscles as they wish. Included is detail on the difference between akinesia and dyskinesia (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - December 10, 2017 Category: Neurology Tags: Parkinson's Disease Source Type: news
Medical News Today: Tardive dyskinesia: What you need to know
Tardive dyskinesia is a side effect of some drugs that causes unintended muscle movements, usually in the face. Learn about which medications cause it. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 29, 2017 Category: Consumer Health News Tags: Schizophrenia Source Type: news
Motor system pathology in psychosis - Walther S, Mittal VA.
PURPOSE OF REVIEW: Motor abnormalities are an intrinsic feature of psychosis. Neurological soft signs, Parkinsonism, dyskinesia, and other motor phenomena are frequently observed in subjects at clinical or genetic risk for psychosis as well as first-episod... (Source: SafetyLit)
Source: SafetyLit - November 6, 2017 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
FDA approves pivotal trial for Insightec ’ s Exablate Neuro in Parkinson ’ s
Insightec said today that it won FDA approval for a pivotal trial of its Exablate Neuro device in treating refractory Parkinson’s disease.
Haifa, Israel-based Insightec said the the study will evaluate using Exablate Neuro’s MR-guided focused ultrasound to ablate portions of the globus pallidus in the brain, which helps regulate voluntary movement. The trial, led by principal investigator Dr. Howard Eisenberg of the University of Maryland, aims to treat dyskinesia in patients with advanced Parkinson’s who have not responded to medication.
“Insightec remains committed to advancing research to expand...
Source: Mass Device - October 25, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Food & Drug Administration (FDA) Imaging Radiosurgery INSIGHTEC Source Type: news
Medical News Today: What you need to know about dyskinesia
We look at dyskinesia, including the main symptoms and treatment options. Learn more about this condition that results in involuntary movements here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 19, 2017 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news
Neurocrine Announces FDA Approval of 80 mg INGREZZA(R) (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD)
First and only TD therapy taken as one capsule, once per day; new 80 mg capsule expected to be available for patients within two weeks
INBRACE program offers patients access to treatment and patient assistance
SAN DIEGO, Oct. 5, 2017 -- (Healthcare ... Biopharmaceuticals, Neurology, FDA Neurocrine Biosciences, INGREZZA, valbenazine, tardive dyskinesia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 5, 2017 Category: Pharmaceuticals Source Type: news
ICER publishes draft report on 3 tardive dyskinesia therapies
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2017 Category: Drugs & Pharmacology Source Type: news
9 Brand New Drugs for Primary Care
COPD … nasal polyps.. gout …. dyskinesia in Parkinson Disease: here’s a brief look at new drugs for these and other disorders coming your way. (Source: ConsultantLive)
Source: ConsultantLive - September 28, 2017 Category: Internal Medicine Authors: Susan Kweskin Tags: COPD Gout Source Type: news
Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia
Antipsychotic medication can cause tardive dyskinesia (TD) – late-onset, involuntary, repetitive movements, often involving the face and tongue. TD occurs in> 20% of adults taking antipsychotic medication (first-generation antipsychotics for> 3 months), with this proportion increasing by 5% per year among those who continue to use these drugs. The incidence of TD among those taking newer antipsychotics is not different from the rate in people who have used older-generation drugs in moderate doses. Studies of TD have previously been found to be limited, with no treatment approach shown to be effective.
To summarise the ...
Source: Current Awareness Service for Health (CASH) - September 25, 2017 Category: Consumer Health News Source Type: news
Second Tardive Dyskinesia Drug Okayed
(MedPage Today) -- Deutetrabenazine (Austedo) joins valbenazine (Ingrezza) in TD indication (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - August 31, 2017 Category: Neurology Source Type: news
FDA OKs Deutetrabenazine (Austedo) for Tardive Dyskinesia FDA OKs Deutetrabenazine (Austedo) for Tardive Dyskinesia
The drug was also approved for chorea associated with Huntington ' s disease earlier in this year.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 31, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news
